Ultragenyx reports interim Phase I/II data for DTX301 in OTC deficiency

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reported interim data from three evaluable patients in the first cohort of a Phase I/II trial evaluating a single peripheral IV infusion of 2x1012 GC/kg DTX301 to

Read the full 312 word article

User Sign In